Novartis: positive phase III results in breast cancer.

(CercleFinance.com) - On Wednesday Novartis reported positive results from a phase III trial on a Kisqali combination therapy in premenopausal women with advanced or metastatic breast cancer.


The trial met its primary endpoint of progression-free survival in women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer, the Swiss firm said.

More than 670 women ranging from 25-58 years in age were randomised in the trial.


Copyright (c) 2017 CercleFinance.com. All rights reserved.